ROOTSTOWN, Ohio--(BUSINESS WIRE)--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could ...
ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, ...
BM-3103 is a first-in-class topical mTOR inhibitor that promotes autophagy to clear mutant keratin aggregates in epidermolysis bullosa simplex. The Food and Drug Administration (FDA) has granted Fast ...
The patient has the Hallopeau-Siemens variant of dystrophic epidermolysis bullosa (EB). EB comprises a group of rare genetic states that are characterized by extremely fragile skin and recurrent ...
The four main types of epidermolysis bullosa (EB): dystrophic epidermolysis bullosa (DEB), epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS) are ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Diacerein 1% did not outperform vehicle in study ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with epidermolysis bullosa simplex treated with ...
As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results